The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CRISPR/cas13-medIated RNA tarGeting tHerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06031727
Recruitment Status : Recruiting
First Posted : September 11, 2023
Last Update Posted : November 13, 2023
Sponsor:
Collaborators:
Tianjin Medical University Eye Hospital
Eye & ENT Hospital of Fudan University
Information provided by (Responsible Party):
HuidaGene Therapeutics Co., Ltd.

Brief Summary:
Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD. nAMD is primarily driven by the perturbation of vascular endothelial growth factor (VEGF). VEGF overexpression leads to abnormal growth of choroidal neovascularization (CNV), which is a hallmark of AMD. Although anti-VEGF agents are effective in treating nAMD, long-term efficacy decreases over time due to the need for repeated injections impacting patient compliance with treatment regimen while patients still may lose vision during the 7th or 8th year of treatment. These frequent intravitreal injections can increase the risk of complications, including submacular hemorrhage, intraocular hypertension, inflammation, and retinal detachment. Furthermore, there are up to 46% of nAMD patients using anti-VEGF agents who have shown poor response or have developed tachyphylaxis with anti-VEGF therapies. HG202 is a CRISPR/Cas13 RNA-editing therapy packaging novel high-fidelity Cas13 technology using one single AAV vector to partially knock-down the expression of VEGFA and thus inhibit CNV formation in AMD patients who are either responsive or non-responsive to anti-VEGF agents. The long-term, stable delivery of HG202 following a one (1) time gene-editing therapy treatment for nAMD could potentially reduce the frequent injection treatment burden of currently available therapies AND treat nAMD patients who are non-responsive to anti-VEGF therapies and have no treatment.

Condition or disease Intervention/treatment Phase
Neovascular Age-related Macular Degeneration(nAMD) Genetic: HG202 Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor A (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Actual Study Start Date : September 4, 2023
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : June 27, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HG202 Genetic: HG202
Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.




Primary Outcome Measures :
  1. Incidence and severity of ocular and systemic adverse events [ Time Frame: 24 weeks ]
    Number of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)


Secondary Outcome Measures :
  1. Incidence and severity of ocular and systemic adverse events [ Time Frame: 48 weeks ]
    Number of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

  2. Change from baseline in best-corrected visual acuity (BCVA) [ Time Frame: 24 and 48 weeks ]
    Change from baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) chart in the study eye at different doses

  3. Change from baseline in central retinal thickness (CRT) [ Time Frame: 24 and 48 weeks ]
    Change from baseline in central retinal thickness (CRT) as measured by optical coherence tomography (OCT) in the study eye at different doses

  4. Change From baseline in annualized rate of supplemental injections [ Time Frame: 48 weeks ]
    Change from baseline in the number of anti-VEGF injections which is annualized to a per year rate in the study eye at different doses



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females ≥ 50 and ≤ 80 years at the time of signing the ICF
  • Diagnosed of choroidal neovascularization (CNV) secondary to AMD in the study eye;
  • Best-corrected visual acuity (BCVA) ranged from 73 to 23 early treatment diabetic retinopathy study (ETDRS)letter score (corresponding to 20/32 to 20/320 of Snellen visual acuity) in the study eye;
  • BCVA in the non-study eye had an ETDRS letter score of 19(equivalent to Snellen visual acuity20/400) and above;
  • Able to perform visual acuity and retinal function tests and able and willing to comply with study procedures for this clinical trial;

RESPONSIVE SUBJECTS:

  • History of need for and responsive to anti-VEGF therapy in the study eye

NON-RESPONSIVE SUBJECTS:

  • History of receiving anti-VEGF therapy but is resistant to treatment, which is defined as: a. complete or near-complete remission of subretinal fluid after the initial 3 doses of anti-VEGF agents and thenno improvement (less than 50um reduction) or deterioration of CRT by OCT

Exclusion Criteria:

  • Subretinal hemorrhage, scarring, or fibrosis of greater than 50% of the total lesion in the study eye;
  • Any condition in the Investigator's opinion that could limit visual improvement in the study eye;
  • Other ocular diseases that may affect central vision in the study eye (e.g., retinal vein occlusion, retinal detachment, macular hole, optic nerve disease, etc.);
  • Presence of CNV not due to nAMD in the study eye,
  • Uncontrolled glaucoma in the study eye;
  • Active intraocular inflammation or a history of uveitis in either eye;
  • History or presence of corneal dystrophy in the study eye;
  • Subjects with immunodeficiency diseases prone to opportunistic infections;
  • History of other intraocular surgery in the study eye within 3 months prior to baseline that in the Investigator's opinion could impact healing or study outcome interpretation;
  • Prior gene therapy or oligonucleotide therapy;
  • History of acute coronary syndrome, myocardial infarction, coronary revascularization, cerebrovascular accident, or transient ischemic attack within 6 months prior to the Screening Visit;
  • Other conditions judged by the investigator as inappropriate for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06031727


Contacts
Layout table for location contacts
Contact: Study Director +86 021-25076143 HG20201@huidagene.com

Locations
Layout table for location information
China, Shanghai
Eye & ENT Hospital of Fudan University Recruiting
Shanghai, Shanghai, China
Contact: Gezhi Xu, PhD    +86 18017316316    drxugezhi@163.com   
China, Tianjing
Tianjin Medical University Eye Hospital Recruiting
Tianjin, Tianjing, China
Contact: Xiaorong Li, PhD    +86 18622818042    Xiaorli@163.com   
Sponsors and Collaborators
HuidaGene Therapeutics Co., Ltd.
Tianjin Medical University Eye Hospital
Eye & ENT Hospital of Fudan University
Investigators
Layout table for investigator information
Study Director: Study Director Huidagene Therapeuticd Co., Ltd.
Layout table for additonal information
Responsible Party: HuidaGene Therapeutics Co., Ltd.
ClinicalTrials.gov Identifier: NCT06031727    
Other Study ID Numbers: HG20201
First Posted: September 11, 2023    Key Record Dates
Last Update Posted: November 13, 2023
Last Verified: November 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by HuidaGene Therapeutics Co., Ltd.:
Macular Degeneration/nAMD/wAMD/Gene-editing/CRISPR/HG202
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases